PROSTATE CRYOABLATION
CLINICAL PUBLICATIONS

Clinical Guidelines, Expert Opinions

  1. National Institute for Health and Clinical Excellence (NICE). Focal Therapy Using Cryoablation For Localised Prostate Cancer. April 2012.
  2. Heidenreich A, Bastian PJ and Zattoni F et. al. Guidelines on Prostate Cancer. European Associations of Urology 2013.
  3. van den Bos W, Muller BG and Scardino PT et. al. Focal Therapy in Prostate Cancer: International Multidisciplinary Consensus on Trial Design. Eur Urol 2014; 65(6):1078-83.
  4. Jarow JP, Thompson IM and Morton Jr. RA et. al. Drug and Device Development for Localized Prostate Cancer: 2014 Report of a Food and Drug Administration (FDA) / American Urological Association (AUA) Public Workshop. Urology 2014.

Epidemiology

  1. Colin SM, Martin RM and Metcafe C et. al. Prostate-cancer mortality in the USA and UK in 1975-2004: an ecological study. Lancet Oncol 2008; 9(5) 445-52.
  2. Karavitakis M, Ahmed HU and Winkler MH et. al. Trends in Pathologic Outcomes After Introduction of Active Surveillance in the UK: Implication for Focal Therapy. The Prostate 2012; 72:1464-8.

Clinical Overview (Paper Reviews)

  1. Bozzini G, Colin P and Betrouni N et. al. Focal therapy of prostate cancer: energies and procedures. Urologic Oncology: Seminars and Original Investigations 31 (2013) 155–67.
  2. Ganzer R, Fritsche HM and Blana A et. al. Fourteen-year oncological and functional outcomes of high-intensity focused ultrasound in localized prostate cancer. 2013 BJU International.
  3. Resnick MJ, Koyama T and Penson DF et. al. Long-Term Functional Outcomes after Treatment for Localized Prostate Cancer. N Engl J Med. 2013 January 31; 368(5): 436–45.

Diagnosis and Disease Identification

  1. Johnstone PAS, Rossi PJ and Master V et. al. ‘Insignificant’ prostate cancer on biopsy: pathologic results from subsequent radical prostatectomy. Prostate Cancer and Prostatic Diseases (2007) 10, 237–41.
  2. Isariyawongse BK, Leon S and Moul JS et al. Significant Discrepancies Between Diagnostic and Pathologic Gleason Sums in Prostate Cancer: The Predictive Role of Age and Prostate-Specific Antigen. Urology 2008 (72): 882–6.
  3. Taira AV, Merric k GS and Wallner KE et al. Performance of transperineal template-guided mapping biopsy in detecting prostate cancer in the initial and repeat biopsy setting. Prostate Cancer Prostatic Dis (13) 2009.

Patient Selection

  1. Ward JF and Pisters LL. Considerations for Patient Selection for Focal Therapy. Ther Adv Urol 2013; 5(6) 330-37.
  2. Passoni NM and Polascik TJ. How to Select the Right Patients for Focal Therapy of Prostate Cancer? Curr Opin Urol 2014 (24): 203-208.

Clinical Studies

  1. Guazzoni G. Focal therapy for organ confined prostate cancer: an investigative prospective pilot study [ClinicalTrials.gov identifier NCT00928603]. ClinicalTrials.gov Web site
  2. Ward JF. Regional cryoablation for localized adenocarcinoma of the prostate [ClinicalTrials.gov identifier NCT00877682]. ClinicalTrials. gov Web site
  3. Eastham J. A phase II study of focal cryoablation in low-risk prostate cancer [ClinicalTrials.gov identifier NCT00774436]. ClinicalTrials. gov Web site

Clinical Studies Outcome

  1. Bahn DK, Silverman P and Rewcastle JC et. al. Focal prostate cryoablation: initial results show cancer control and potency preservation. J Endourol 2006; 20(9) 688-92.
  2. Lambert EH, Bolte K and Katz AE. Focal cryosurgery: encouraging health outcomes for unifocal prostate cancer. Urology 2007; 69(6): 1117-20.
  3. Ellis DS, Manny Jr TB and Rewcastle JC. Cryoablation as primary treatment for localized prostate cancer followed by penile treatment rehabilitation. Urology 2007; 69(2):306-10.
  4. Onik G, Vaughan D and Brady J et. al. “Male lumpectomy”: focal therapy for prostate cancer using cryoablation. Urology 2007; 70(Suppl): 16-21.
  5. Onik G, Vaughan D, Lotenfoe R, et al. The “male lumpectomy”: Focal therapy for prostate cancer using cryoablation results in 48 patients with at least 2-year follow-up. Urol Oncol 2008;26:500 –5.
  6. Truesdale MD, Cheetham PJ and Katz AE et. al. An Evaluation of Patient Selection Criteria on Predicting Progression-Free Survival After Primary Focal Unilateral Nerve-Sparing Cryoablation for Prostate Cancer Recommendations for Follow Up. The Cancer Journal 2010, 16: 544-9.
  7. Bahn D., De Castro Abreu A.L., Gill I.S. et al. Focal cryosurgery for clinically unilateral, lowintermediate risk prostate cancer in 73 men with a median follow-up of 3,7 years. Eur Urol 2012 ; 62 : 55-63.
  8. Ward JF and Jones JS. Focal cryotherapy for localized prostate cancer: a report from the national Cryo On-Line Database (COLD) Registry. BJU Int 2012; 109: 1648-54.
  9. Hale Z., Miyake M. and Rosser CJ et. al. Focal cryosurgical ablation of the prostate: a single institute’s perspective. BMC Urology 2013, 13:2.

Salvage Prostate Cryoablation

  1. Babaian RJ, Donnelly B and Thrasher JB, et. al. Best practice statement on cryosurgery for the treatment of localized prostate cancer. J Urol. 2009; 180: 1993-2004.
  2. Schwandt A and Garcia JA. Complications of androgen deprivation therapy in prostate cancer. Curr Opinion Urol 2009; 19: 322-6.
  3. Malcolm JB, Fabrizio MD and Schellhammer PF, et. al. Quality of life after open or robotic prostatectomy, cryoablation or brachytherapy for localized prostate cancer. J Urol 2010; 183: 1822- 1829.
  4. Cheetham P. and Katz A., et. al. Long-Term Cancer-Specific and Overall Survival for Men Followed More Than 10 Years After Primary and Salvage Cryoablation of the Prostate. J. of Endourology 2010; 24(7): 1123–9.
  5. Finley DS and Belldegrun AS. Salvage cryotherapy for radiation-recurrent prostate cancer: outcomes and complications. Curr Urol Rep. 2011; 12(3): 209-15.
  6. Williams AK, Martı´nez CH and Chin JL, et. al. Disease-free survival following salvage cryotherapy for biopsyproven radio-recurrent prostate cancer. Eur Urol. 2011; 60: 405-10.
  7. Mouraviev V, Spiess PE and Jones SJ. Salvage cryoablation for locally recurrent prostate cancer following primary radiotherapy. Eur Urol. 2012; 61:1204-11.
  8. NCCN 2011 guidelines version 1.2012 prostate cancer. PROS-7.
  9. Spiess PE, Levy DA and Jones JS, et. al. Predictors of biochemical failure in patients undergoing prostate wholegland salvage cryotherapy: a novel risk stratification model. BJUI 2013; doi: 10.1111/j.1464-410X.2012.11695.
  10. Wenske S, Quarrier S and Katz A. Salvage cryosurgery of the prostate for failure after primary radiotherapy or cryosurgery: long-term clinical, functional, and oncological outcomes in a large cohort at a tertiary referral centre. Eur Urol. 2013; 64: 1-7.
  11. Bjerklund Johansen TE, Witzsch U. and Greene D. Salvage treatment in prostate cancer: a clinical approach. Expert Rev Anticancer Ther. 2013; 13: 613-23.
  12. Ahmad I, Kalna G and Leung HY, et. al. Prostate gland lengths and iceball dimensions predict micturition functional outcome following salvage prostate cryotherapy in men with radiation recurrent prostate cancer. PLOS ONE 2013; 8.
  13. Friedlander FD, Gu X and Hu JC et. al. Population-based Comparative Effectiveness of Salvage Radical Prostatectomy vs Cryotherapy. Urology 2014 (83): 653-7.

Primary Prostate Cryoablation

  1. Babaian RJ, Donnelly B and Thrasher JB, et. al. Best practice statement on cryosurgery for the treatment of localized prostate cancer. J Urol. 2009; 180: 1993-2004.
  2. Malcolm JB, Fabrizio MD and Schellhammer PF, et. al. Quality of life after open or robotic prostatectomy, cryoablation or brachytherapy for localized prostate cancer. J Urol 2010; 183: 1822-9.
  3. Kimura M, Mouraviev V and Polascik TJ, et. al. Analysis of urinary function using validated instruments and uroflowmetry after primary and salvage prostate cryoablation. Urology 2010; 76:1258-65.
  4. Cheetham P. and Katz A., et. al. Long-Term Cancer-Specific and Overall Survival for Men Followed More Than 10 Years After Primary and Salvage Cryoablation of the Prostate. J. of Endourology 2010; 24(7): 1123–9.
  5. Dhar N., Ward J.F., and Jones J.S. et. al. Primary Full-Gland Prostate Cryoablation in Older Men (> Age of 75 Years): Results from 860 Patients Tracked with the COLD Registry. BJU International 2011; 108: 508-12.
  6. Cohen J.K., Miller Jr. R.J., and Baust J. et. al. Ten-Year Biochemical Disease Control for Patients with Prostate Cancer Treated with Cryosurgery as Primary Therapy. Urology 2008; 71: 515–18.